alzheimer's disease Clinical Trials and Research
Also known as: alzheimer's, ad, senile dementia of the alzheimer type, dementia, alzheimer's type, primary degenerative dementia, late-onset alzheimer's, early-onset alzheimer's · ICD-10: G30
Alzheimer's disease is a progressive brain disorder that gradually destroys memory and thinking skills. Clinical trial research is actively exploring new ways to prevent, treat, and even cure the disease, focusing on its underlying biological mechanisms. Find a Trial helps patients and caregivers search for active studies.
Search alzheimer's disease trials →
Common questions about alzheimer's disease clinical trials
What types of clinical trials are currently investigating Alzheimer's disease?
Research focuses on new drugs to target amyloid and tau proteins, improve cognitive function, and manage behavioral symptoms. Studies also explore lifestyle interventions, diagnostic tools, and ways to prevent the disease. Data from ClinicalTrials.gov and NIH RePORTER show diverse research areas.
Who is eligible to participate in Alzheimer's disease clinical trials?
Eligibility criteria vary greatly by study, often including age, specific diagnostic criteria for Alzheimer's or mild cognitive impairment, and overall health status. Some trials seek participants at early stages, while others focus on advanced disease. Detailed criteria are listed on ClinicalTrials.gov.
What are common interventions being studied in Alzheimer's trials?
Common interventions include investigational medications aimed at reducing amyloid plaques or tau tangles in the brain. Other studies explore non-drug approaches like cognitive training, diet, exercise, and novel technologies. Research data is available on ClinicalTrials.gov and NIH RePORTER.
What are the different phases of clinical trials for Alzheimer's disease?
Clinical trials progress through phases: Phase 1 tests safety in a small group; Phase 2 evaluates effectiveness and side effects in a larger group; Phase 3 confirms effectiveness and monitors side effects in an even larger group. Phase 4 studies occur after a treatment is approved.
Are there specific biomarkers important in Alzheimer's disease research?
Yes, biomarkers like amyloid beta and tau levels in cerebrospinal fluid or detected by PET scans are crucial for diagnosis and tracking disease progression. Genetic markers, such as APOE4, are also studied to understand risk and response to treatments. This research is often detailed on NIH RePORTER.
What are common reasons someone might not be eligible for an Alzheimer's trial?
Common exclusion criteria can include other neurological conditions, significant heart or kidney disease, certain medications, or a history of stroke. Some trials exclude participants based on specific genetic profiles or if their cognitive impairment is due to another cause. Eligibility is strictly defined for safety and study integrity.
Do participants in Alzheimer's clinical trials have to pay for treatment or study visits?
Generally, study-related medical care, tests, and investigational treatments in clinical trials are provided at no cost to the participant. However, standard medical care not related to the study, or travel expenses, may or may not be covered. Specifics are outlined in the informed consent process.
What are researchers hoping to learn from current Alzheimer's disease studies?
Researchers aim to discover treatments that can slow, stop, or reverse the disease's progression, improve cognitive function, and alleviate behavioral symptoms. They also seek better diagnostic tools and a deeper understanding of the disease's causes. This ongoing work is documented on ClinicalTrials.gov and NIH RePORTER.
How to find a alzheimer's disease trial that fits you
- Describe your alzheimer's disease situation in detail — stage if applicable, prior treatments, age, and other relevant conditions.
- Use the location filter (worldwide, US, US & Canada, Europe) to narrow to trials near you.
- Review each trial's eligibility criteria carefully. Save 2–5 candidates with their NCT numbers.
- Discuss with your treating clinician before contacting the research site.
Browse all alzheimer's disease trials →